Literature DB >> 17942543

Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.

Anokhi J Kapasi1, Deborah H Spector.   

Abstract

We previously reported that defined components of the host transcription machinery are recruited to human cytomegalovirus immediate-early (IE) transcription sites, including cdk9 and cdk7 (S. Tamrakar, A. J. Kapasi, and D. H. Spector, J. Virol. 79:15477-15493, 2005). In this report, we further document the complexity of this site, referred to as the transcriptosome, through identification of additional resident proteins, including viral UL69 and cellular cyclin T1, Brd4, histone deacetylase 1 (HDAC1), and HDAC2. To examine the role of cyclin-dependent kinases (cdks) in the establishment of this site, we used roscovitine, a specific inhibitor of cdk1, cdk2, cdk7, and cdk9, that alters processing of viral IE transcripts and inhibits expression of viral early genes. In the presence of roscovitine, IE2, cyclin T1, Brd4, HDAC1, and HDAC2 accumulate at the transcriptosome. However, accumulation of cdk9 and cdk7 was specifically inhibited. Roscovitine treatment also resulted in decreased levels of cdk9 and cdk7 RNA. There was a corresponding reduction in cdk9 protein but only a modest decrease in cdk7 protein. However, overexpression of cdk9 does not compensate for the effects of roscovitine on cdk9 localization or viral gene expression. Delaying the addition of roscovitine until 8 h postinfection prevented all of the observed effects of the cdk inhibitor. These data suggest that IE2 and multiple cellular factors needed for viral RNA synthesis accumulate within the first 8 h at the viral transcriptosome and that functional cdk activity is required for the specific recruitment of cdk7 and cdk9 during this time interval.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942543      PMCID: PMC2224385          DOI: 10.1128/JVI.01681-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption.

Authors:  S Müller; A Dejean
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 2.  RNA polymerase II carboxy-terminal domain kinases: emerging clues to their function.

Authors:  Gregory Prelich
Journal:  Eukaryot Cell       Date:  2002-04

3.  Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication.

Authors:  Ayumi Kudoh; Tohru Daikoku; Yutaka Sugaya; Hiroki Isomura; Masatoshi Fujita; Tohru Kiyono; Yukihiro Nishiyama; Tatsuya Tsurumi
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

4.  Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes.

Authors:  Jianxin You; Jennie L Croyle; Akiko Nishimura; Keiko Ozato; Peter M Howley
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

5.  The specificities of protein kinase inhibitors: an update.

Authors:  Jenny Bain; Hilary McLauchlan; Matthew Elliott; Philip Cohen
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

6.  Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production.

Authors:  Veronica Sanchez; Anita K McElroy; Judy Yen; Sama Tamrakar; Charles L Clark; Rachel A Schwartz; Deborah H Spector
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus.

Authors:  Shannon L Taylor; Paul R Kinchington; Andrew Brooks; Jennifer F Moffat
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Phosphorylation of the RNA polymerase II carboxyl-terminal domain in human cytomegalovirus-infected cells and in vitro by the viral UL97 protein kinase.

Authors:  Moon-Chang Baek; Paula M Krosky; Angela Pearson; Donald M Coen
Journal:  Virology       Date:  2004-06-20       Impact factor: 3.616

9.  Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors.

Authors:  Prerna Diwan; Jonathan J Lacasse; Luis M Schang
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  The differential requirement for cyclin-dependent kinase activities distinguishes two functions of herpes simplex virus type 1 ICP0.

Authors:  David J Davido; William F Von Zagorski; Gerd G Maul; Priscilla A Schaffer
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  36 in total

1.  Use of ATP analogs to inhibit HIV-1 transcription.

Authors:  Aarthi Narayanan; Gavin Sampey; Rachel Van Duyne; Irene Guendel; Kylene Kehn-Hall; Jessica Roman; Robert Currer; Hervé Galons; Nassima Oumata; Benoît Joseph; Laurent Meijer; Massimo Caputi; Sergei Nekhai; Fatah Kashanchi
Journal:  Virology       Date:  2012-07-06       Impact factor: 3.616

2.  Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation.

Authors:  Sujayita Roy; Ran He; Arun Kapoor; Michael Forman; Jennifer R Mazzone; Gary H Posner; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

Review 3.  Differences between mouse and human cytomegalovirus interactions with their respective hosts at immediate early times of the replication cycle.

Authors:  Gerd G Maul; Dmitri Negorev
Journal:  Med Microbiol Immunol       Date:  2008-02-09       Impact factor: 3.402

4.  The interaction of the gammaherpesvirus 68 orf73 protein with cellular BET proteins affects the activation of cell cycle promoters.

Authors:  Matthias Ottinger; Daniel Pliquet; Thomas Christalla; Ronald Frank; James P Stewart; Thomas F Schulz
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

5.  Biologic and immunologic effects of knockout of human cytomegalovirus pp65 nuclear localization signal.

Authors:  John A Zaia; Xiuli Li; Anne E Franck; Xiwei Wu; Lia Thao; Ghislaine Gallez-Hawkins
Journal:  Clin Vaccine Immunol       Date:  2009-04-15

6.  Cyclin-dependent Kinases Phosphorylate the Cytomegalovirus RNA Export Protein pUL69 and Modulate Its Nuclear Localization and Activity.

Authors:  Sabine Rechter; Gillian M Scott; Jan Eickhoff; Katrin Zielke; Sabrina Auerochs; Regina Müller; Thomas Stamminger; William D Rawlinson; Manfred Marschall
Journal:  J Biol Chem       Date:  2009-01-29       Impact factor: 5.157

7.  Recruitment of cdk9 to the immediate-early viral transcriptosomes during human cytomegalovirus infection requires efficient binding to cyclin T1, a threshold level of IE2 86, and active transcription.

Authors:  Anokhi J Kapasi; Charles L Clark; Karen Tran; Deborah H Spector
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 8.  Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents.

Authors:  A E Leitch; C Haslett; A G Rossi
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

9.  The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.

Authors:  Jitka Holcakova; Peter Tomasec; Joachim J Bugert; Eddie Cy Wang; Gavin Wg Wilkinson; Roman Hrstka; Vladimir Krystof; Miroslav Strnad; Borivoj Vojtesek
Journal:  Antivir Chem Chemother       Date:  2010-01-05

10.  Cyclin-dependent kinase activity controls the onset of the HCMV lytic cycle.

Authors:  Martin Zydek; Christian Hagemeier; Lüder Wiebusch
Journal:  PLoS Pathog       Date:  2010-09-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.